Product information and disease descriptionPlace of product in therapyApproaches to treatment
Expected outcomes of therapy
9 evidence topics · 8 sources
Summary: expected outcomes
STRIDE-II sets clinical remission and endoscopic healing as long-term treatment targets, adds absence of disability and restoration of quality of life, and sets symptomatic relief and normalization of serum and fecal markers as short-term targets; histological healing in ulcerative colitis is not a formal target. The ACG 2025 guideline recommends treating to endoscopic improvement (Mayo endoscopic subscore 0 or 1) to increase the likelihood of sustained steroid-free remission and to prevent hospitalization and surgery, and the ECCO 2026 guideline describes treat-to-target beyond steroid-free clinical remission as not yet conclusively validated. In the pooled ABTECT induction trials, the placebo-adjusted clinical remission rate at Week 8 with obefazimod 50 mg was 16.4%. In the ABTECT maintenance trial, clinical remission at Week 44 was 50.8% with 25 mg and 51.3% with 50 mg against 10.4% with placebo among 580 induction responders. At week 8 of induction, 37% of participants on 50 mg reported no bowel urgency against 18.1% on placebo. In Study 108, 68% (88/130) of participants were in clinical remission at week 144 after dose reduction to 25 mg. These obefazimod results come from press releases and congress presentations; no peer-reviewed full report of ABTECT has been published.
Treatment targets: STRIDE-II
“STRIDE-II confirmed STRIDE-I long-term targets of clinical remission and endoscopic healing and added absence of disability, restoration of quality of life, and normal growth in children. Symptomatic relief and normalization of serum and fecal markers have been determined as short-term targets. Transmural healing in Crohn's disease and histological healing in ulcerative colitis are not formal targets but should be assessed as measures of the remission depth.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Goals of management: ACG 2025
Mucosal and histologic healing and long-term outcomes: ECCO 2026
Obefazimod: clinical remission and secondary endpoints after 44 weeks of maintenance
Obefazimod: patient-reported outcomes after 8 weeks of induction
Obefazimod: durability of clinical remission over three years
Health-related quality of life expected with comparator advanced therapies
“During induction, clinically meaningful improvements in IBDQ were observed with upadacitinib, filgotinib, and guselkumab. During maintenance, upadacitinib 30 mg and vedolizumab showed HRQoL benefits, although clinical meaningfulness was not consistently demonstrated.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote